Latest News for: rnai

Edit

RNAi Technologies, Companies & Markets, 2028 - ResearchAndMarkets.com

Business Wire 04 Nov 2021
DUBLIN--(BUSINESS WIRE)--The "RNAi ... Various markets relevant to RNAi are analyzed from 2018 to 2028.
Edit

Outlook on the RNAi Drug Delivery Global Market to 2026 - by Application, Technology and Region

PR Newswire 29 Oct 2021
29, 2021 /PRNewswire/ -- The "RNA Interference (RNAi) Drug Delivery Market ... The global RNA interference (RNAi) drug delivery market exhibited strong growth during 2015-2020. Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations.
Edit

RNAi Platform Characterisation Results (e-Therapeutics plc)

Public Technologies 26 Oct 2021
RNAi Platform Characterisation Results ... ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, today announces the results of the Company's RNAi platform characterisation studies ... Benchmarking studies included one approved RNAi drug and one currently in registration.
Edit

Interim Results, July 2021 and RNAi Platform Development Presentation (e-Therapeutics plc)

Public Technologies 26 Oct 2021
Successful RNAi Platform ... Competitive proprietary RNAi platform developed ... Scope for future partnerships, across computational and RNAi platforms ... Significantly strengthened cash position to facilitate a number of initiatives, expanding the Company's platform capabilities and acceleration of the development of in-house RNAi pipeline.
Edit

Global RNA Analysis Market Report 2021-2026 - Focus on Microarrays, Polymerase Chain Reaction (PCR), Sequencing Technologies, and RNAi Gene Silencing

PR Newswire 21 Oct 2021
This report analyzes and assesses different types of RNA analysis involved, namely microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing ... as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing.
Edit

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of ...

Business Wire 29 Sep 2021
ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results ...
Edit

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society (Alnylam Pharmaceuticals Inc)

Public Technologies 29 Sep 2021
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society ... ALNY), the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership ... About RNAi.
Edit

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate ...

Business Wire 28 Sep 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD ... .
Edit

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder (Dicerna Pharmaceuticals Inc)

Public Technologies 28 Sep 2021
DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD, Dicerna's investigational GalXC™ RNAi therapeutic in development for the treatment of alcohol use disorder (AUD).
Edit

2021-2027 Global and Regional Antisense and RNAi Therapeutics Industry Production, Sales and Consumption Status and ...

MENA FN 09 Aug 2021
(MENAFN - Data Lab Forecast) Report Description The Global Antisense and RNAi Therapeutics Market Report provides Insightful information to the clients enhancing their basic leadership capacity ... .
Edit

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues (Alnylam Pharmaceuticals Inc)

Public Technologies 29 Jul 2021
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues ... ALNY), the leading RNAi therapeutics company, and PeptiDream, Inc ... About RNAi.
Edit

Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications

The Record 21 Jul 2021
NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc ... BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.
Edit

Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent (Arbutus Biopharma Corp)

Public Technologies 07 Jul 2021
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent ... AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes using Arbutus' novel covalently conjugated ...
×